REHOVOT, Israel, May
7, 2019 /PRNewswire/ -- Evogene Ltd.
(NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company
developing novel products for life science markets, announced today
that it will release its financial results for the first quarter of
2019 on Tuesday, May 28, 2019. Dr.
Arnon Heyman, CEO of Evogene's
cannabis subsidiary, Canonic, will join the conference call to
discuss the company's activity with highlights from Canonic's
presentation, which can be found on Evogene's website under the
investor relations section.
On the day of the announcement, the Company's management will
host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call,
please dial 1-888-668-9141 toll free from the United States, or +972-3-918-0609
internationally. Access to the call will also be available via live
webcast through the Company's website at www.evogene.com.
A replay of the conference call will be available approximately
three hours following the completion of the call. To access the
replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5904
internationally. The replay will be accessible through May 28, 2019, and an archive of the webcast will
be available on the Company's website through June 8, 2019.
About Evogene:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a leading
biotechnology company developing novel products for major life
science markets through the use of a unique computational
predictive biology (CPB) platform incorporating deep scientific
understandings and advanced computational technologies.
Today, this platform is utilized by the Company to discover and
develop innovative products in the following areas (via
subsidiaries or divisions): ag-chemicals, ag-biologicals, seed
traits, integrated castor oil ag-solutions, human microbiome based
therapeutics and medical cannabis. Each subsidiary or division
establishes its product pipeline and go-to-market, as demonstrated
in its collaborations with world-leading companies such as BASF,
Corteva, Bayer and ICL. For more information, please visit
www.evogene.com
Forward Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be
identified by words such as "may", "could",
"expects", "intends", "anticipates",
"plans", "believes", "scheduled", "estimates" or words of
similar meaning. Such statements are based on current
expectations, estimates, projections and assumptions,
describe opinions about future events, involve certain
risks and uncertainties which are difficult to predict and are
not guarantees of future performance. Therefore, actual future
results, performance or achievements of Evogene may differ
materially from what is expressed or implied
by such forward-looking statements due to a variety of
factors, many of which beyond Evogene's
control, including, without limitation, those risk
factors contained in Evogene's reports filed with the
appropriate securities authority. Evogene disclaims any
obligation or commitment to update these forward-looking statements
to reflect future events or developments or changes in
expectations, estimates, projections and assumptions.
Evogene Investor
Contact:
Nir
Zalik
IR Director
IR@evogene.com
972-8-931-1900
US Investor Relations:
Vivian
Cervantes
PCG Investor Relations
vivian@pcgadvisory.com
646-863-6274
View original
content:http://www.prnewswire.com/news-releases/evogene-financial-results-for-the-first-quarter-of-2019-300845098.html
SOURCE Evogene